U.S. markets close in 5 hours 39 minutes

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.69+0.19 (+2.18%)
As of 10:21AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close8.50
Bid8.59 x 900
Ask8.62 x 1000
Day's Range8.59 - 8.73
52 Week Range7.40 - 18.93
Avg. Volume430,231
Market Cap465.512M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-1.80
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CARA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cara Therapeutics, Inc.
    CARA: Lowering target price to $7.00CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Simply Wall St.

    Here's Why We're Not Too Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Situation

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • GlobeNewswire

    Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

    STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company’s financial operations. “Ryan’s deep financial leadership experience will be instrument

  • Benzinga

    Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

    Cara Therapeutics Inc (NASDAQ: CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica (NP). Notalgia paresthetica (NP) is a nerve disorder that causes intense and sometimes painful itching in the back impacting quality of life. The data will be presented at the European Academy of Dermatology and Venereology (EADV) Congress. The presentation includes data from 125 patients with NP and moderate-to-severe pruri